USD 2.27
(-8.85%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 73.06 Million USD | 50.29% |
2022 | 48.5 Million USD | -24.48% |
2021 | 64.23 Million USD | -71.47% |
2020 | 225.15 Million USD | 926.35% |
2019 | -27.24 Million USD | -114.79% |
2018 | 184.2 Million USD | 71498.84% |
2017 | -258 Thousand USD | -2.38% |
2016 | -252 Thousand USD | -6.78% |
2015 | -236 Thousand USD | 0.0% |
2014 | - USD | -100.0% |
2013 | 4.97 Billion USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2002 | - USD | 0.0% |
2001 | - USD | 100.0% |
2000 | -784 Thousand USD | -14.75% |
1999 | -683.22 Thousand USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 58.21 Million USD | -54.4% |
2024 Q1 | 127.66 Million USD | 513.99% |
2023 FY | 72.9 Million USD | 50.29% |
2023 Q4 | 20.79 Million USD | 0.97% |
2023 Q2 | 19 Million USD | 49.88% |
2023 Q1 | 12.67 Million USD | -13.51% |
2023 Q3 | 20.59 Million USD | 8.38% |
2022 Q4 | 14.65 Million USD | 17.51% |
2022 Q3 | 12.47 Million USD | 29.06% |
2022 Q2 | 9.66 Million USD | -17.47% |
2022 Q1 | 11.71 Million USD | 13.41% |
2022 FY | 48.5 Million USD | -24.48% |
2021 Q4 | 10.32 Million USD | 16.66% |
2021 Q3 | 8.85 Million USD | -77.22% |
2021 FY | 64.23 Million USD | -71.47% |
2021 Q1 | 6.19 Million USD | -22.09% |
2021 Q2 | 38.85 Million USD | 527.37% |
2020 Q2 | 211.83 Million USD | 11610.23% |
2020 FY | 225.15 Million USD | 926.35% |
2020 Q1 | 1.8 Million USD | 104.86% |
2020 Q3 | 3.55 Million USD | -98.32% |
2020 Q4 | 7.95 Million USD | 123.44% |
2019 Q4 | -37.25 Million USD | 21.24% |
2019 FY | -27.24 Million USD | -114.79% |
2019 Q1 | 99.11 Million USD | -26.58% |
2019 Q2 | -41.8 Million USD | -142.18% |
2019 Q3 | -47.3 Million USD | -13.14% |
2018 Q3 | -41.55 Million USD | -5.13% |
2018 Q4 | 135 Million USD | 424.9% |
2018 FY | 184.2 Million USD | 71498.84% |
2018 Q1 | -40.94 Million USD | 72.26% |
2018 Q2 | -39.52 Million USD | 3.46% |
2017 Q2 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 FY | -258 Thousand USD | -2.38% |
2017 Q4 | -147.6 Million USD | 0.0% |
2016 FY | -252 Thousand USD | -6.78% |
2016 Q2 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 FY | -236 Thousand USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 FY | - USD | -100.0% |
2013 Q2 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 FY | 4.97 Billion USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
2003 Q2 | - USD | 0.0% |
2003 Q1 | - USD | 0.0% |
2002 FY | - USD | 0.0% |
2002 Q4 | - USD | 0.0% |
2002 Q3 | - USD | 0.0% |
2002 Q2 | - USD | 0.0% |
2002 Q1 | - USD | 0.0% |
2001 Q2 | -741 Thousand USD | -3.78% |
2001 Q1 | -714 Thousand USD | -244.53% |
2001 FY | - USD | 100.0% |
2001 Q4 | - USD | 0.0% |
2001 Q3 | - USD | 100.0% |
2000 Q2 | -428 Thousand USD | -5.93% |
2000 Q1 | -404.05 Thousand USD | 0.0% |
2000 Q4 | 494 Thousand USD | 211.26% |
2000 FY | -784 Thousand USD | -14.75% |
2000 Q3 | -444 Thousand USD | -3.74% |
1999 FY | -683.22 Thousand USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Editas Medicine, Inc. | -99.52 Million USD | 173.414% |
Dynavax Technologies Corporation | 182.11 Million USD | 59.879% |
Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 86.049% |
Perrigo Company plc | 1.68 Billion USD | 95.652% |
Illumina, Inc. | 2.74 Billion USD | 97.337% |
Thermo Fisher Scientific Inc. | 15.22 Billion USD | 99.52% |
Iovance Biotherapeutics, Inc. | -9.56 Million USD | 863.82% |
Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.725% |
IQVIA Holdings Inc. | 5.23 Billion USD | 98.605% |
Heron Therapeutics, Inc. | 10.04 Million USD | -627.614% |
Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.353% |
Unity Biotechnology, Inc. | -19.69 Million USD | 470.917% |
Waters Corporation | 1.76 Billion USD | 95.851% |
Biogen Inc. | 7.3 Billion USD | 98.999% |
Sangamo Therapeutics, Inc. | -45.32 Million USD | 261.207% |
Evolus, Inc. | 140.52 Million USD | 48.005% |
Adicet Bio, Inc. | -6.09 Million USD | 1298.213% |
Cara Therapeutics, Inc. | 14.79 Million USD | -393.896% |
bluebird bio, Inc. | -4.03 Million USD | 1913.077% |
FibroGen, Inc. | 128.9 Million USD | 43.317% |
Agilent Technologies, Inc. | 3.46 Billion USD | 97.891% |
Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 334.432% |
Homology Medicines, Inc. | -7.22 Million USD | 1110.748% |
Geron Corporation | -123.5 Million USD | 159.162% |
Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 95.186% |
Amicus Therapeutics, Inc. | 362.03 Million USD | 79.817% |
Myriad Genetics, Inc. | 476.4 Million USD | 84.663% |
Viking Therapeutics, Inc. | -292 Thousand USD | 25122.945% |
Intellia Therapeutics, Inc. | -398.79 Million USD | 118.322% |
Zoetis Inc. | 5.83 Billion USD | 98.748% |
Abeona Therapeutics Inc. | 302 Thousand USD | -24094.371% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 96.631% |
BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 96.163% |
Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.151% |
Kala Pharmaceuticals, Inc. | -303 Thousand USD | 24214.521% |
Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 90.615% |
Atara Biotherapeutics, Inc. | -313 Thousand USD | 23444.089% |
Verastem, Inc. | -62 Thousand USD | 117950.0% |
Nektar Therapeutics | 53.47 Million USD | -36.63% |
Axsome Therapeutics, Inc. | 244.53 Million USD | 70.12% |
Aclaris Therapeutics, Inc. | -85.21 Million USD | 185.743% |
Sarepta Therapeutics, Inc. | 1.09 Billion USD | 93.315% |
OPKO Health, Inc. | 318.12 Million USD | 77.032% |
Exelixis, Inc. | 1.75 Billion USD | 95.843% |
Neurocrine Biosciences, Inc. | 1.84 Billion USD | 96.045% |
Corcept Therapeutics Incorporated | 475.89 Million USD | 84.646% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 2.21 Million USD | -3198.736% |
Imunon, Inc. | -720 Thousand USD | 10248.124% |
Blueprint Medicines Corporation | 236.58 Million USD | 69.116% |
Insmed Incorporated | 239.63 Million USD | 69.509% |
Halozyme Therapeutics, Inc. | 636.89 Million USD | 88.528% |
Agios Pharmaceuticals, Inc. | 17.31 Million USD | -321.889% |
TG Therapeutics, Inc. | 219.1 Million USD | 66.653% |
Incyte Corporation | 3.44 Billion USD | 97.876% |
Emergent BioSolutions Inc. | 343.9 Million USD | 78.753% |